148 related articles for article (PubMed ID: 21852261)
1. Ovarian cancer treatments on the horizon.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
[No Abstract] [Full Text] [Related]
2. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
3. Avastin's uncertain future in breast cancer treatment.
Twombly R
J Natl Cancer Inst; 2011 Mar; 103(6):458-60. PubMed ID: 21393607
[No Abstract] [Full Text] [Related]
4. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
5. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
6. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
7. A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.
Winer I; Buckanovich RJ
Gynecol Oncol; 2010 Mar; 116(3):578-9. PubMed ID: 19897232
[No Abstract] [Full Text] [Related]
8. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
9. Regulatory considerations on endpoints in ovarian cancer drug development.
Balasubramaniam S; Kim GS; McKee AE; Pazdur R
Cancer; 2017 Jul; 123(14):2604-2608. PubMed ID: 28499075
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
11. [Low-grade serous, mucinous carcinoma].
Nakayama K; Kyo S
Gan To Kagaku Ryoho; 2015 Feb; 42(2):179-82. PubMed ID: 25834916
[No Abstract] [Full Text] [Related]
12. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
13. Avastin hearing leads to more uncertainty over drug's future.
Goozner M
J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
[No Abstract] [Full Text] [Related]
14. Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer.
Bellati F; Gasparri ML; Caccetta J; Palaia I; Benedetti panici P
J Surg Oncol; 2012 Sep; 106(4):529; author reply 527-8. PubMed ID: 22488017
[No Abstract] [Full Text] [Related]
15. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
Chamberlain MC
Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
[No Abstract] [Full Text] [Related]
16. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
17. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
18. [Hyperthermic intraperitoneal chemotherapy in the treatment for recurrent ovarian cancer].
Giseĭnov KD; Beliaev AM; Senchik KIu; Maksimov SIa; Urmancheeva AF; Gafton GI; Mikaia NA; Beliaeva OA; Kireeva GS; Gorodnova TV; Matveeva NS
Vopr Onkol; 2014; 60(3):343-7. PubMed ID: 25033688
[TBL] [Abstract][Full Text] [Related]
19. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
Tewari KS; Java JJ; Gatcliffe TA; Bookman MA; Monk BJ
Gynecol Oncol; 2014 Jun; 133(3):439-45. PubMed ID: 24657300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
